Company Snapshot: BGEN  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Biogen Opens Community Laboratory, State-Of-The-Art Teaching Facility

   BIOGEN OPENS COMMUNITY LABORATORY
Biogen's Chairman and CEO James C. Mullen addresses students at the opening of the Biogen Community Laboratory. (PRNewsFoto)[TK]
CAMBRIDGE, MA USA
   BIOGEN LOGO
Biogen Logo. (PRNewsFoto)[KC]
CAMBRIDGE, MA USA
     Collaborates with Cambridge Public Schools on Biotechnology Program

    CAMBRIDGE, Mass., Aug. 22 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) today opened the Biogen Community Laboratory, a
state-of-the-art teaching facility where nearly 50 Cambridge Rindge and Latin
School students have enrolled in a summer program on molecular genetics.
    (Photo:  http://www.newscom.com/cgi-bin/prnh/20020822/NETH018
             http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
    The Community Lab is located inside one of Biogen's research and
development buildings at the Company's headquarters in Cambridge.  The 1,100
square-foot facility is outfitted with the latest lab equipment and
technology, and will serve Cambridge Public School students.
    Biogen's Chairman and Chief Executive Officer James C. Mullen said,
"Biogen is pleased to play a role in the educational enrichment of young
people.  The Community Lab will offer exciting educational opportunities and
provide students with a glimpse of how science can be applied to careers in
biotechnology.  We have worked closely with the Cambridge Public Schools and
the City to bring the Community Lab to life, and we look forward to continuing
to work together to ensure it remains a resource that supports the work being
done in classrooms and aids in the development of future scientists."
    Superintendent of Cambridge Public Schools, Bobbie D'Alessandro said, "I
commend Biogen for establishing the Community Lab, the first program of its
kind in Cambridge.  We are delighted that Cambridge students will benefit from
Biogen's world-class understanding of biology and gain exposure to the world
of biotechnology.  We appreciate that Biogen is making this important
contribution to the future of Cambridge students and the entire community."
    Biogen launched the Community Lab with two one-week summer sessions, the
first of which began this week.  Cambridge Rindge and Latin 11th- and 12th-
graders are participating in a variety of experiments including extracting DNA
from living cells and purifying proteins from bacteria.  Biogen scientists
lead discussions on the technology and applications used to develop and
discover novel therapeutics.  Biogen is also working on the summer program
with the Dolan DNA Learning Center of Cold Spring Harbor Laboratory, the
world's first science center devoted entirely to public genetics education.
    During the academic year, classes will visit the Community Lab and conduct
similar experiments.  Biogen also anticipates using the facility for employee
and adult education programs.
    Cambridge City Councillor Anthony Galluccio also spoke at the ceremony.
City officials, business and education leaders, and Biogen employees also
attended the event.

    About Biogen
    Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from worldwide sales of AVONEX(R)
(Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis,
and from the sales by licensees of a number of products. (Please see full
prescribing information at http://www.avonex.com.) Biogen's research and
development activities are focused on novel products to treat inflammatory and
autoimmune diseases, neurological diseases, cancer, fibrosis and congestive
heart failure. The Company maintains active clinical research programs in
protein therapeutics, small molecules, genomics and gene therapy. For copies
of press releases and additional information about the Company, please consult
Biogen's homepage on the World Wide Web at http://www.biogen.com.



SOURCE Biogen, Inc.




Back to Topback to top

Related links:
  • http://www.biogen.com
    Photo Notes:
    NewsCom: 
    http://www.newscom.com/cgi-bin/prnh/20020822/NETH018
    http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
    PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840
    Company News On-Call:
  • http://www.prnewswire.com/comp/101550.html
    CONTACT:
    Amy Brockelman, Manager, Public Affairs,
    +1-617-679-3860; or Christina Dillon, Manager, Investor
    Relations, +1-617-679-2521, both of Biogen, Inc.